Biomemory
Biomemory builds DNA-based molecular data storage appliances for enterprise and government data centers, offering rackable servers and synthetic DNA Cards with 150-year retention, S3-compatible integration, and claimed 20x TCO reduction versus traditional cold storage.
- Company typePrivate
- Founded2021
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biomemory does
Biomemory is a Paris-headquartered biotechnology company, founded in 2021, that develops DNA-based molecular data storage appliances engineered for enterprise and government data center environments. The company's core platform consists of two integrated components: the DNA Data Storage Server, a rackable appliance with an S3-compatible interface, modular architecture, and industrialized end-to-end write/store/read processes; and the DNA Card, a proprietary synthetic DNA storage medium offering up to 150 years of retention and readability, ultra-low energy consumption at rest, biosecure air-gapped design, and claimed enterprise-grade resilience beyond 10E-16 UBER. Underlying technology includes proprietary enzymatic DNA block assembly, supplemented in 2026 by acquired Catalog Technologies capabilities in high-speed DNA printing, high-throughput reading, and molecular computing.
Biomemory serves large-scale enterprise data centers, regulated and high-security organizations (national archives, healthcare records, genomic data), and cybersecurity-sensitive government and defense customers. Named deployments and engagements include Thales (national security and cybersecurity), SICPA (identity security), CNES (French space agency), and Bordeaux-Métropole (municipal archival). The company pursues an enterprise field sales motion with long deployment cycles extending into 2030-2031.
The business model spans three streams: hardware sales of DNA Data Storage Servers and DNA Cards; managed services across Services, Managed, and Deployed models; and recurring revenue from value-added software features such as Search and Compute. Pricing is not publicly disclosed; the company's economic narrative rests on claimed 20x TCO reduction over 10 years and 10x footprint reduction versus traditional cold storage solutions. Distribution is direct enterprise sales supplemented by a strategic OEM-style integration with Scality, which embeds Biomemory's DNA tier into Scality's object storage infrastructure. The company maintains its Paris headquarters and a Boston regional office acquired through the Catalog Technologies transaction, targeting a commercial data center deployment in H2 2026 and exabyte-scale capacity by 2030.
Biomemory firmographics
Firmographics- Name
- Biomemory
- Legal name
- Biomemory
- Website
- https://biomemory.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biomemory builds DNA-based molecular data storage appliances for enterprise and government data centers, offering rackable servers and synthetic DNA Cards with 150-year retention, S3-compatible integration, and claimed 20x TCO reduction versus traditional cold storage.
- Ownership category
- akta.pro rank
Biomemory industry classification
Industry- Product category
- Enterprise Data Storage Hardware
- NAICS
- Computer Storage Device Manufacturing (334112), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
- SIC
- Computer Storage Devices (3572), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where Biomemory is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Biomemory business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- DNA Data Storage Hardware: Sale of DNA data storage servers and DNA Card appliances for data center environments. Hardware designed for rackmount deployment with modular architecture enabling seamless hardware upgrades and long-term compatibility
- Managed Services: Managed service offerings supporting various business models including Services, Managed, and Deployed deployment options with progressive feature additions
- Enterprise Software Features: Additional value-added functionalities such as Search and Compute capabilities delivered as feature upgrades within the molecular storage platform
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Biomemory product offering
Product offeringCore offering
Biomemory develops IT-friendly DNA Data Storage servers and DNA Card media for data center environments. The platform translates binary digital content into synthetic DNA strands stored in rackable appliances, providing an ultra-durable, energy-efficient cold storage tier with up to 150-year retention, S3-compatible integration, and air-gapped biosecurity.
Product overview
Biomemory offers a unified DNA data storage platform consisting of the DNA Data Storage Server as the core hardware appliance and DNA Card as the proprietary storage medium. The DNA Card slots into the DNA Data Storage Server, which provides the industrialized end-to-end write/store/read processes and interoperable S3 interface for seamless integration into existing data center multi-tier architectures. The platform targets cold storage and long-term archival applications with claims of 150-year retention, enterprise-grade resilience, and 20x TCO reduction versus traditional cold storage solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- DNA Data Storage Server Rackable DNA data storage server designed for data center environments, featuring an interoperable S3 interface, modular architecture, and end-to-end write/store/read processes for molecular data storage. Targeted at enterprise and government customers needing long-term cold storage and high-security archival.
- DNA Card Synthetic DNA storage medium contained in a card format that slots into the DNA Data Storage Server, providing long-term data retention (up to 150 years), ultra-low energy consumption at rest, biosecure air-gapped protection, and scalable rack-level density.
Quantifiable outcome
- Up to 20x TCO reduction over 10 years vs traditional cold storage solutions
- +4 more outcomes
Companies that use Biomemory
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Biomemory technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Biomemory partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- ScalitycoreStrategic partnership to develop DNA-based long-term archival storage solutions integrated as a secure, ultra-long-term archival tier within Scality's existing object storage infrastructures. Targets 150-year data retention for applications including national archives and healthcare records. Marks Scality's entry into DNA archival storage.
- Catalog TechnologiesflagshipAsset acquisition combining Catalog's scalable high-speed printing and high-throughput reading capabilities with Biomemory's enzymatic DNA block assembly. Enables launch of commercial DNA data storage solution in H2 2026 and establishes North American footprint with Boston flagship office for R&D, production, and customer support.
Scale indicators6 records
Recent moves6 records
Expansion highlights7 records
Biomemory competitors and assessment
Company assessmentDirect peers
- Catalog Technologies: Boston-based DNA data storage and computing pioneer whose assets were acquired by Biomemory in March 2026. Directly comparable technology stack (DNA print, store, read) and was the most direct competing commercial DNA storage venture prior to acquisition.
- Iridia: Emerging DNA data storage company developing semiconductor-based enzymatic synthesis for archival storage. Targets the same DNA-as-storage end-market and represents the most direct active competitor to Biomemory's rackable appliance approach.
Broad incumbents
- Twist Bioscience: Public DNA synthesis company with a DNA data storage division and silicon-based synthesis platform. Comparable as a scaled DNA synthesis incumbent with adjacent storage activity, broader synthetic biology portfolio, and significantly greater capital resources.
- Quantum Corporation: Long-established enterprise tape and cold storage vendor whose LTO-based products are the primary incumbent solution for the long-term archival workloads Biomemory targets. Directly comparable customer base and use cases even though the underlying storage medium differs.
- Spectra Logic: Enterprise tape archive specialist serving media & entertainment, government, and research customers. Comparable as the de facto incumbent for 30+ year cold/archival retention tiers that Biomemory's 150-year claim is designed to disrupt.
- IBM: Co-developer of the LTO tape standard and operator of large hyperscale data center infrastructure. Comparable both as an incumbent cold-storage technology provider and as a potential strategic acquirer or partner for molecular storage technology.
- Seagate: Mass-volume HDD manufacturer pushing HAMR-based high-density drives for cold and warm storage tiers. Directly competes for the same enterprise storage budgets and continues to drive down cost per terabyte in the cold storage tier.
- Western Digital: Major HDD and enterprise storage vendor whose high-capacity drives are widely deployed in data center cold tiers. Comparable as an incumbent competing on cost-per-terabyte and density against Biomemory's molecular alternative.
Emerging players
- DNA Script: Enzymatic DNA synthesis company whose underlying synthesis chemistry is comparable to Biomemory's enzymatic block assembly. Relevant as a potential supplier or competitor in the enzymatic DNA synthesis value chain underpinning DNA storage.
Others
- Scality: Object storage software vendor with whom Biomemory has a strategic partnership to integrate DNA storage as an archival tier. Adjacent participant that serves as both distribution channel and a comparable in the enterprise object storage ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Biomemory social profiles
Digital presenceBiomemory compliance and trust
Trust signalCompliance1 record
Biomemory financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomemory leadership team
Management profileNumber of profiles
Profiles1 record
Biomemory funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomemory M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomemory
What does Biomemory do?
Biomemory develops IT-friendly DNA Data Storage servers and DNA Card media for data center environments. The platform translates binary digital content into synthetic DNA strands stored in rackable appliances, providing an ultra-durable, energy-efficient cold storage tier with up to 150-year retention, S3-compatible integration, and air-gapped biosecurity.
Is Biomemory a public or private company?
Biomemory is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biomemory founded?
Biomemory was founded in 2021. It employs 11 to 50 people.
Where is Biomemory based?
Biomemory is headquartered in Paris, France, in the Europe region.
How does Biomemory make money?
Three revenue lines are on record. DNA Data Storage Hardware is the primary driver. The others are managed Services and enterprise Software Features.
Who are Biomemory's main competitors?
Direct peers on record are Catalog Technologies and Iridia. Broad incumbents are Twist Bioscience, Quantum Corporation, Spectra Logic, IBM, Seagate and Western Digital. DNA Script is listed as an emerging player. Scality is listed as an others.
Does Biomemory have an API?
No public API is recorded for Biomemory.
What industry is Biomemory in?
Biomemory's product category is Enterprise Data Storage Hardware. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 334112 and its SIC code is 3572.